Cyxone develops novel drugs to improve quality of life for patients suffering from autoimmune diseases
Cyxone AB is a clinical biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The company’s drug portfolio is based on two technological pillars in the form of oral molecules and cyclotide-based drugs that inhibit key processes in the body’s cells that are typically associated with various immune-related disorders.
Cyxone’s technologies have the potential to address an unmet need to develop new effective and safe medicines that can improve the quality of life for patients affected by autoimmune diseases. The company’s development portfolio comprises Rabeximod in a clinical phase II program for RA and T20K that has successfully completed phase I infusion study for MS.
Press Releases
The Medical University of Vienna has filed a new patent application for extended protection of T20K, included in Cyxone’s license agreement
March 23 2020Cyxone investigates listing on Nasdaq Main Market Nordic Small Cap
March 3 2020Year-end Report 1 January to 31 December 2019
February 14 2020Regulatory
Events
Cyxone will attend the BIOEurope conference in Munich, Germany, 26-28 October 2020.